Shopping Cart
- Remove All
- Your shopping cart is currently empty
Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively. This compound demonstrates potent anti-proliferative effects and induces cell cycle arrest in cancer cells, applicable in research concerning HR-positive, HER2-negative breast cancer, and hepatocellular carcinoma [1] [3] [4].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | 8-10 weeks | |
50 mg | Inquiry | 8-10 weeks |
Description | Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively. This compound demonstrates potent anti-proliferative effects and induces cell cycle arrest in cancer cells, applicable in research concerning HR-positive, HER2-negative breast cancer, and hepatocellular carcinoma [1] [3] [4]. |
Targets&IC50 | CDK4-CyclinD3:9 nM, CDK4-CyclinD1:11 nM, CDK6-CyclinD2:16 nM, DYRK1A:2000 nM, MAPK:8000 nM |
In vitro | Palbociclib orotate, at concentrations ranging from 0–1 μM over 24 hours, effectively inhibits Ser 795 phosphorylation in MDA-MB-435 cells, demonstrating an IC50 of 0.063 μM, and similarly impacts Ser 780 and Ser 795 phosphorylation in Colo-205 colon carcinoma cells [1]. At a wider concentration range of 0–10 μM for the same duration, it induces a G1 phase cell cycle arrest in MDA-MB-453 cells [1]. When administered at 500 nM for seven days, palbociclib orotate upregulates homologous gene expression (H2d1, H2k1, and B2m) in both MDA-MB-453 and MDA-MB-361 cells [2]. Additionally, with extended exposure of six days, palbociclib orotate suppresses the growth of various luminal ER-positive and HER2-amplified breast cancer cell lines, with IC50 values spanning from 4 nM to 1 μM [3]. Over a three-day period, it also limits the proliferation of human liver cancer cell lines with IC50 values between 0.01 μM and 3.49 μM and causes reversible cell cycle arrest [4]. |
In vivo | Palbociclib orotate, administered orally at doses of 75 or 150 mg/kg daily for 14 days, induces rapid tumor regression and impedes tumor growth [1]. At a dose of 90 mg/kg for 12 days, it also decreases Treg cell quantities and alters the Treg:CD8 ratio in the spleen and lymph nodes of tumor-free mice, highlighting its tumor-independent actions [2]. Furthermore, when given at 100 mg/kg for a week, palbociclib orotate exhibits potent anti-tumor effects in a genetically engineered mosaic mouse model of liver cancer [4]. |
Alias | PD 0332991 orotate |
Molecular Weight | 603.63 |
Formula | C29H33N9O6 |
Cas No. | 2757498-64-7 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.